CochranLab@CochranLab
Check out our review article describing recent updates in LAG3 biology and therapeutics in @TrendsinPharma with @jwang133 and @Curie_Bio colleagues:
002558
- CochranLab@CochranLabProud to have our work with @CarolynBertozzi and Ron Levy on tumor-targeted cancer therapeutics featured in the @StanfordOTL annual report now being developed at TwoStep Therapeutics, led by lab alum Caitlyn Miller @CaitlynBioE003245
- CochranLab@CochranLabCongrats to lab alum Bob Chen and the @OmniAbTech team on winning "Best in Show" at @PEGSboston for their innovative and impactful xPloration B cell/ Ab screening platform.PEGS Summit @PEGSboston🏆 Congratulations to @OmniAbTech , Inc. — winner of the Best of Show Award at #PEGSummit 2025! Their xPloration® Partner Access Program captured attendee votes by a landslide for its innovation and impact. Thanks to all who participated, and congrats again to the OmniAb team!003290
PEGS Summit@PEGSboston🏆 Congratulations to @OmniAbTech , Inc. — winner of the Best of Show Award at #PEGSummit 2025! Their xPloration® Partner Access Program captured attendee votes by a landslide for its innovation and impact. Thanks to all who participated, and congrats again to the OmniAb team!
125607- CochranLab@CochranLabExcited to see our lab's B cell screening technology, spearheaded by Cochran alum and xCella Biosciences co-founder Bob Chen, rolled out as a now commercial instrument from antibody discovery company @OmniAbTech.OmniAb @OmniAbTechOmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit003201
- CochranLab@CochranLabCochranLabRT @bioe_stanford: Congratulations to Professor Jennifer Cochran @CochranLab who was recently elected to the National Academy of Engineering @theNAEng for protein discovery and development, biotechnology entrepreneurship, and leadership in academic bioengineering!030727
- CochranLab@CochranLabCochranLabRT @Jack_Silb: I'm excited to share our work "Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function" that's now out in PNAS! 1/3 Link to paper: Link to press release:0602.9K
- CochranLab@CochranLabCochranLabRT @J_Immunol: #JI_TopRead from @CaitlynBioE @CochranLab @CarolynBertozzi @StanfordHealth | #TLR9 agonist, PIP-CpG, enhances the CD8 #Tcell response to spontaneous tumors | #ReadTheJI #immunology #AuthorChoice #FreetoRead #TumorImmunology 👉0707.9K
- CochranLab@CochranLabCochranLabRT @ACIR_org: In the physiologically relevant MMTV-PyMT GEMM model, @CaitlynBioE @BarfiIdit @CarolynBertozzi demonstrated that systemic delivery of a tumor integrin-targeted TLR9 agonist (PIP-CpG) led to sustained elimination [...]0309.6K
- CochranLab@CochranLabCochranLabRT @CaitlynBioE: Thrilled to announce that our new PIP-CpG paper is now live @J_Immunol . PIP-CpG is a tumor-targeting immunotherapy that is in preclinical development & we are hoping to advance it to the clinic in the coming years. . A 🧵👇(1/13)012017.9K
- CochranLab@CochranLabCongrats to joint @StanfordBioE PhD student @hollander_mj, @CarolynBertozzi and team for this exciting collaborative work!002732
- CochranLab@CochranLabCochranLabRT @LongwoodLeaders: Wonderful insights and leadership from @Stanford @StanfordMed @CochranLab @KarlDeisseroth @drcwestphal #Longwoodhealthcareleaders020546
- CochranLab@CochranLabCochranLabRT @Stanford_ChEMH: Congratulations to faculty fellows @alaurenoconnell, @CyertMartha & Jennifer Cochran @CochranLab for winning the 2022 @StanfordMedOFDD Faculty Women’s Forum Awards! Learn more:030
- CochranLab@CochranLabCochranLabRT @raviradhak: Immensely enjoyed the reviewing experience and spending the day-and-a-half on @Stanford campus with this special group of people @kumarlabucb @Widya__Mulya @chubaoyolu @TejalADesai and Darelene Soloman of @Agilent. Thank you @StanfordBioE @CochranLab for the hospitality!Kumar Lab, UC Berkeley @kumarlabucbHonored to serve on the External Review Committee for @StanfordBioE last week! Inspiring dept, brilliantly led by @CochranLab. Plus the views are pretty nice... Joined by @Widya__Mulya, @chubaoyolu, and @raviradhak, along w @TejalADesai and Darlene Solomon (not shown). 🌲010
Kumar Lab, UC Berkeley@kumarlabucbHonored to serve on the External Review Committee for @StanfordBioE last week! Inspiring dept, brilliantly led by @CochranLab. Plus the views are pretty nice... Joined by @Widya__Mulya, @chubaoyolu, and @raviradhak, along w @TejalADesai and Darlene Solomon (not shown). 🌲
0021- CochranLab@CochranLabCochranLabRT @PEGSboston: Join #PEGS22 Plenary Keynote Jennifer Cochran, PhD, today at 4:10pm to discuss challenges and opportunities in developing non-antibody protein therapeutics.010
- CochranLab@CochranLabCochranLabRT @Evoletto: TLR9 (CpG) agonist was chemically conjugated to polyspecific integrin-binding peptide (PIP) that is capable to localise various types of solid tumours as explained by Caitlyn Miller from @CochranLab at @Stanford #PEGS22 @PEGSboston030
- CochranLab@CochranLabExcited to share this collaborative work published in Cell on an exquisite drug-regulated CAR platform. Led by Louai Labanieh, jointly advised Bioengineering PhD student in the lab of @cm35cLouai Labanieh @LouaiLabaniehThrilled to announce that our SNIP paper is live @CellCellPress! SNIP is a high-performance drug-regulated CAR platform that is optimized for the clinic--plans for a trial are already underway @StanfordMed. #CART #Immunotherapy #SynBio #Cancer. 1/0114
Louai Labanieh@LouaiLabaniehThrilled to announce that our SNIP paper is live @CellCellPress! SNIP is a high-performance drug-regulated CAR platform that is optimized for the clinic--plans for a trial are already underway @StanfordMed. #CART #Immunotherapy #SynBio #Cancer. 1/1543192- CochranLab@CochranLabCochranLabRT @CellPressNews: Read Jennifer Cochran's recent @CellChemBiol article: Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression @CochranLab #AACR22020
- CochranLab@CochranLabThrilled to share our exciting collaborative work with @CarolynBertozzi, Ron Levy, @SCIDirector Steve Artandi featured on the cover of @CellChemBiol, led by the talented @CaitlynBioE and @BarfiIdit.Caitlyn Miller @CaitlynBioEExcited to see our research featured on the cover of this month’s issue of @CellChemBiol. Check out our article “Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression” at @CarolynBertozzi016
Caitlyn Miller@CaitlynBioEExcited to see our research featured on the cover of this month’s issue of @CellChemBiol. Check out our article “Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression” at @CarolynBertozzi
2669- CochranLab@CochranLabCochranLabRT @Majzner_Lab: Happy to share our lab's first manuscript. In work led by @JTheruvath_MD, we tested a combo of FDA approved anti-GD2 with blockade of CD47, a macrophage checkpoint. Blocking CD47 unleashes patients' macrophages to phagocytose or 'eat' cancer cells. Combo was highly effective! 1/Saheli Sadanand @SaheliSadanand📢 New in @NatureMedicine! Great work led by @Majzner_Lab @JTheruvath_MD shows that the combo of anti-GD2 + CD47 blockade ⬆️ anti-tumor activity in 🐭 models of #neuroblastoma, #osteosarcoma & #lungcancer by modulating #macrophage activity #immunotherapy0320
Saheli Sadanand@SaheliSadanand📢 New in @NatureMedicine! Great work led by @Majzner_Lab @JTheruvath_MD shows that the combo of anti-GD2 + CD47 blockade ⬆️ anti-tumor activity in 🐭 models of #neuroblastoma, #osteosarcoma & #lungcancer by modulating #macrophage activity #immunotherapy21458- CochranLab@CochranLabOn July 19, learn about how next-generation engineered proteins target stromal factors can remodel an immunosuppressive tumor microenvironment at the #PEGSymposium
002 - Show more posts
